diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index 8a55608ba..1c68ddd10 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -113,6 +113,12 @@ Aon's temporal cost analysis shows medical costs rise 23% in year 1 but grow onl International generic competition beginning January 2026 (Canada patent expiry, immediate Sandoz/Apotex/Teva filings) creates price compression trajectory faster than 'inflationary through 2035' assumes. Oral Wegovy launched at $149-299/month (5-8x reduction vs $1,300/month injectable). China/India generics projected at $40-50/month by 2030. Aon 192K patient study shows break-even timing is highly price-sensitive: at $1,300/month, multi-year retention required; at $50-150/month, Aon data suggests cost savings within 12-18 months under capitation. The 'inflationary through 2035' conclusion holds at current US pricing but becomes invalid if international generic arbitrage and oral formulation competition compress effective prices to $50-150/month range by 2030. Scope qualification needed: claim is valid conditional on pricing trajectory assumptions that are now challenged by G7 patent cliff precedent. + +### Additional Evidence (challenge) +*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-19* + +Aon's 192K patient dataset shows medical costs grow only 2% for GLP-1 users after 12 months versus 6% for non-users, with diabetes patients showing 6-9 percentage point lower cost growth at 30 months. This suggests the 'inflationary through 2035' projection may only hold for short-term payers who don't capture the post-12-month savings trajectory. + --- Relevant Notes: diff --git a/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md b/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md index f02739da1..656c676d1 100644 --- a/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md +++ b/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md @@ -66,6 +66,12 @@ Medicare modeling quantifies the compound value: 38,950 CV events avoided, 6,180 Aon's 192K patient study found adherent GLP-1 users (80%+) had 47% fewer MACE hospitalizations for women and 26% for men, with the sex differential suggesting larger cardiovascular benefits for women than previously documented. + +### Additional Evidence (extend) +*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-19* + +Aon's dataset adds cancer risk reduction to the multi-organ protection profile: ~50% lower ovarian cancer and 14% lower breast cancer in female users, plus associations with lower osteoporosis and rheumatoid arthritis. The sex-differential in MACE reduction (47% for women vs 26% for men) suggests protection mechanisms may be stronger or more diverse in women. + --- Relevant Notes: diff --git a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md index f89adfb2a..f8c38bacf 100644 --- a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md +++ b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md @@ -95,6 +95,12 @@ Aon data shows the 80%+ adherent cohort captures dramatically stronger cost redu GLP-1 behavioral adherence failures demonstrate that even breakthrough pharmacology cannot overcome behavioral determinants: patients on GLP-1 alone show same weight regain as placebo without behavior change. This is direct evidence that the 'human constraints' factor (Amodei framework) limits pharmaceutical efficacy independent of drug quality. + +### Additional Evidence (extend) +*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-19* + +Aon data shows adherence is the binding variable for cost-effectiveness: the 80%+ adherent cohort shows 9 percentage point lower cost growth for diabetes and 7 points lower for weight loss versus 6 and 3 points for the full cohort. This means the 15% two-year persistence rate doesn't just undermine economics—it concentrates all the value in the small persistent minority. + --- Relevant Notes: diff --git a/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md b/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md index 0c35f6498..e5d33a2b5 100644 --- a/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md +++ b/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md @@ -49,6 +49,12 @@ The Trump Administration deal establishes a $50/month out-of-pocket maximum for Aon's commercial claims data (employer-sponsored insurance) shows strong adherence effects, but the sample is biased toward higher-income employed populations. The fact that even in this relatively advantaged cohort, adherence is the key determinant of cost-effectiveness supports the claim that affordability barriers in lower-income populations would be even more binding. + +### Additional Evidence (extend) +*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-19* + +Aon's finding that cost-effectiveness requires 80%+ adherence to achieve maximum savings (9 vs 6 percentage point cost reduction for diabetes) means affordability-driven discontinuation doesn't just affect individual outcomes—it prevents the system-level cost savings that would justify broader coverage, creating a self-reinforcing access barrier. + --- Relevant Notes: diff --git a/inbox/queue/.extraction-debug/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.json b/inbox/queue/.extraction-debug/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.json index e73be8207..975fef469 100644 --- a/inbox/queue/.extraction-debug/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.json +++ b/inbox/queue/.extraction-debug/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.json @@ -1,13 +1,13 @@ { "rejected_claims": [ { - "filename": "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md", + "filename": "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-medical-savings-lag-drug-costs-by-12-18-months.md", "issues": [ "missing_attribution_extractor" ] }, { - "filename": "glp-1-female-users-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction.md", + "filename": "glp-1-receptor-agonists-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction-in-female-users.md", "issues": [ "missing_attribution_extractor" ] @@ -19,14 +19,14 @@ "fixed": 2, "rejected": 2, "fixes_applied": [ - "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md:set_created:2026-03-18", - "glp-1-female-users-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction.md:set_created:2026-03-18" + "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-medical-savings-lag-drug-costs-by-12-18-months.md:set_created:2026-03-19", + "glp-1-receptor-agonists-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction-in-female-users.md:set_created:2026-03-19" ], "rejections": [ - "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md:missing_attribution_extractor", - "glp-1-female-users-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction.md:missing_attribution_extractor" + "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-medical-savings-lag-drug-costs-by-12-18-months.md:missing_attribution_extractor", + "glp-1-receptor-agonists-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction-in-female-users.md:missing_attribution_extractor" ] }, "model": "anthropic/claude-sonnet-4.5", - "date": "2026-03-18" + "date": "2026-03-19" } \ No newline at end of file diff --git a/inbox/queue/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.md b/inbox/queue/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.md index 1b57d0a2f..21dcc37c0 100644 --- a/inbox/queue/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.md +++ b/inbox/queue/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.md @@ -7,13 +7,17 @@ date: 2026-01-13 domain: health secondary_domains: [internet-finance] format: report -status: unprocessed +status: enrichment priority: high tags: [glp-1, employer-costs, cancer-risk, cardiovascular, cost-offset, real-world-evidence] processed_by: vida processed_date: 2026-03-18 enrichments_applied: ["glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md"] extraction_model: "anthropic/claude-sonnet-4.5" +processed_by: vida +processed_date: 2026-03-19 +enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -64,3 +68,15 @@ flagged_for_rio: ["GLP-1 cost dynamics have direct implications for health inves - Female GLP-1 users: ~50% lower ovarian cancer incidence, 14% lower breast cancer incidence - Adherent users (80%+): 47% fewer MACE hospitalizations for women, 26% for men - Study released January 13, 2026 + + +## Key Facts +- Aon analyzed 192,000+ GLP-1 users in U.S. commercial health claims data +- First 12 months on Wegovy/Zepbound: medical costs rise 23% vs 10% for non-users +- After 12 months: medical costs grow 2% vs 6% for non-users +- Diabetes indication at 30 months: medical cost growth 6 percentage points lower; 9 points lower with 80%+ adherence +- Weight loss indication at 18 months: cost growth 3 points lower; 7 points lower with consistent use +- Female GLP-1 users: ~50% lower ovarian cancer incidence, 14% lower breast cancer incidence +- Adherent users (80%+): 47% fewer MACE hospitalizations for women, 26% for men +- Study released January 13, 2026 +- Also associated with lower rates of osteoporosis, rheumatoid arthritis, alcohol/drug abuse hospitalizations, bariatric surgery, and certain pancreatic disorders